Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing oral upadacitinib to subcutaneous adalimumab in adults with moderate-to-severe rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED